Evidence map›Paper›PMID 23349769›Full record

ArticlePloS one2013

Glucocorticoid repression of inflammatory gene expression shows differential responsiveness by transactivation- and transrepression-dependent mechanisms.

Elizabeth M King, Joanna E Chivers, Christopher F Rider, Anne Minnich, Mark A Giembycz, Robert Newton

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05078021 (Phenotyping Disease Severity in Asthma), which is not on this map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05078021 unknown statusnot on this mapstarted 2022, after this paper: background citation

Phenotyping Disease Severity in Asthma: Molecular Investigations of Corticosteroid

TypeobservationalSponsorUniversity of CalgaryRan2022 to 2024Enrolled60ConditionsAsthmaArmsBronchoscopy
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 92 citations in OpenAlex.

  1. Trial
  2. Review
  3. Selective Glucocorticoid Receptor Modulators (SEGRAMs): Can They Improve the Therapeutic Index of Steroid Therapy?Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  4. Review
  5. Article
  6. Gout and NLRP3 Inflammasome Biology.Arthritis & rheumatology (Hoboken, N.J.) · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Leukocyte cytokine responses in adult patients with mitochondrial DNA defects.Journal of molecular medicine (Berlin, Germany) · 2022
    Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. A cell permeant phosphopeptide mimetic of Niban inhibits p38 MAPK and restores endothelial function after injury.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Elizabeth M KingAirways Inflammation Research Group, Snyder Institute for Chronic Diseases, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.
Joanna E Chivers
Christopher F Rider
Anne Minnich
Mark A Giembycz
Robert Newton
University of Calgary · CABristol-Myers Squibb (United States) · US

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

Binding of glucocorticoid to the glucocorticoid receptor (GR/NR3C1) may repress inflammatory gene transcription via direct, protein synthesis-independent processes (transrepression), or by activating transcription (transactivation) of multiple anti-inflammatory/repressive factors. Using human pulmonary A549 cells, we showed that 34 out of 39 IL-1β-inducible mRNAs were repressed to varying degrees by the synthetic glucocorticoid, dexamethasone. Whilst these repressive effects were GR-dependent, they did not correlate with either the magnitude of IL-1β-inducibility or the NF-κB-dependence of the inflammatory genes. This suggests that induction by IL-1β and repression by dexamethasone are independent events. Roles for transactivation were investigated using the protein synthesis inhibitor, cycloheximide. However, cycloheximide reduced the IL-1β-dependent expression of 13 mRNAs, which, along with the 5 not showing repression by dexamethasone, were not analysed further. Of the remaining 21 inflammatory mRNAs, cycloheximide significantly attenuated the dexamethasone-dependent repression of 11 mRNAs that also showed a marked time-dependence to their repression. Such effects are consistent with repression occurring via the de novo synthesis of a new product, or products, which subsequently cause repression (i.e., repression via a transactivation mechanism). Conversely, 10 mRNAs showed completely cycloheximide-independent, and time-independent, repression by dexamethasone. This is consistent with direct GR transrepression. Importantly, the inflammatory mRNAs showing attenuated repression by dexamethasone in the presence of cycloheximide also showed a significantly greater extent of repression and a higher potency to dexamethasone compared to those mRNAs showing cycloheximide-independent repression. This suggests that the repression of inflammatory mRNAs by GR transactivation-dependent mechanisms accounts for the greatest levels of repression and the most potent repression by dexamethasone. In conclusion, our data indicate roles for both transrepression and transactivation in the glucocorticoid-dependent repression of inflammatory gene expression. However, transactivation appears to account for the more potent and efficacious mechanism of repression by glucocorticoids on these IL-1β-induced genes.

Indexed as

Blotting, WesternCell Line, TumorCycloheximideCytokinesDexamethasoneGene ExpressionGene Expression ProfilingGlucocorticoidsHumansInflammation MediatorsInterleukin-1betaLinear ModelsNF-kappa BOligonucleotide Array Sequence AnalysisProtein Synthesis InhibitorsReceptors, GlucocorticoidCycloheximideCytokinesDexamethasoneGlucocorticoidsInflammation MediatorsInterleukin-1betaNF-kappa BNR3C1 protein, humanProtein Synthesis InhibitorsReceptors, Glucocorticoid

Identifiers

PMID23349769
PMCPMC3545719
OpenAlexW1981555245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.